Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12995092 | 0.95 | FLT3 (0.39) | FLT3SMN1; SMN2KMT2AFAAHMEN1 | |
| SCHEMBL10096102 | 0.91 | KMT2A (0.38) | SMN1; SMN2KMT2AMEN1MAPTHPGD | |
| SCHEMBL12995271 | 0.90 | SMN1; SMN2 (0.35) | SMN1; SMN2KMT2AFAAHMEN1MAPT | |
| SCHEMBL12995269 | 0.90 | HRH3 (0.34) | FLT3 | |
| SCHEMBL13152413 | 0.87 | KMT2A (0.37) | SMN1; SMN2KMT2AFAAHMEN1MAPT | |
| SCHEMBL12995396 | 0.86 | NPC1 (0.49) | SMN1; SMN2KMT2AMEN1MAPTHPGD | |
| SCHEMBL12995267 | 0.86 | MEN1 (0.39) | SMN1; SMN2KMT2AMEN1MAPTHPGD | |
| SCHEMBL12995219 | 0.86 | KMT2A (0.39) | SMN1; SMN2KMT2AMEN1MAPTHPGD | |
| SCHEMBL10096053 | 0.86 | RAB9A (0.39) | SMN1; SMN2KMT2AMEN1MAPTHPGD | |
| SCHEMBL12995093 | 0.86 | HRH3 (0.35) | FLT3SMN1; SMN2HPGDCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | FLT3 2143/4885SMN1; SMN2 3609/4885KMT2A 4464/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | FLT3 2143/4885SMN1; SMN2 3609/4885KMT2A 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.